All In Biotech

Drug Trial Radar · NCT07717736

Phase 4 Master Protocol for Patients Prescribed Prademagene Zamikeracel for the Treatment of Wounds

Last checked: Nov 19, 2026Latest source record: Aug 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

100

Planned (sponsor's estimate)

Start

Nov 2026

Primary completion

Nov 2031

Study completion Jul 2032

Sponsor

Lead sponsor
Abeona Therapeutics, IncIndustry
Sponsor type
Industry
First posted
Jul 21, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The Master Protocol includes 3 studies (Study A, Study B, and Study C) that will evaluate pz-cel and related processes in the post-marketing setting. Study A investigates the efficacy and safety of non-conforming pz-cel in patients with Recessive Dystrophic Epidermolysis Bullosa (RDEB). Study B enables the collection of additional biopsy samples from patients receiving treatment with pz-cel. Study C assesses the efficacy and safety of pz-cel in patient populations not represented in the VIITAL clinical trial (NCT04227106).

Conditions

  • Epidermolysis Bullosa (EB)
  • Recessive Dystrophic Epidermolysis Bullosa (RDEB)
  • Dystrophic Epidermolysis Bullosa (DEB)

Interventions

  • Non-conforming pz-cel surgical application to RDEB woundsBiological

    Non-conforming pz-cel is pz-cel intended for commercial treatment that did not meet commercial release criteria, but had no safety concerns associated with its use.

  • Additional biopsiesProcedure

    Additional biopsy samples from patients who are expected to receive treatment with pz-cel in the post-marketing setting.

  • Pz-cel surgical application to DEB woundsBiological

    This intervention is for patients requiring special access for application of pz-cel.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Study A - Wound Healing ≥50%Time frame: From Baseline at Week 24 (Month 6)
  2. Study A - Pain Severity Scale (Wong-Baker FACES)Time frame: At Week 24 (Month 6)
  3. Study C - Wound Healing ≥50%Time frame: From Baseline at Week 24 (Month 6)
  4. Study C - Pain Severity Scale (Wong-Baker FACES)Time frame: At Week 24 (Month 6)

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.